Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Biosimilars

Research Grade Eldelumab (HY524016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HY524016
Species reactivityHuman
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHuman
IsotypeIgG1-kappa
Expression system Mammalian Cells
Species Human
Clonality Monoclonal
Target Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10
Endotoxin level Please contact with the lab for this information.
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession P02778
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate NamesBMS-936557, MDX-1100, 946414-98-8
BackgroundEldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.
• The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    Detects CXCL10/IP-10 in indirect ELISAs.

  • SDS-PAGE

    SDS-PAGE for Research Grade Eldelumab.

References
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list